openPR Logo
Press release

Waldenstrom's Macroglobulinaemia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Amgen, Abbvie, Roche, TransThera, BeiGene, Janssen, Ascentage, Gilead, InnoCare Pharma, Mustang Bio

07-17-2023 07:57 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Waldenstrom's Macroglobulinaemia Pipeline Assessment (2023)

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 22+ pipeline drugs in the Waldenstrom's Macroglobulinaemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Waldenstrom's Macroglobulinaemia Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Waldenstrom's Macroglobulinaemia Therapeutics Market.

The report provides a detailed description of the Waldenstrom's Macroglobulinaemia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Waldenstrom's Macroglobulinaemia Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Waldenstrom's Macroglobulinaemia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Waldenstrom's Macroglobulinaemia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Waldenstrom's Macroglobulinaemia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Waldenstrom's Macroglobulinaemia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Waldenstrom's Macroglobulinaemia treatment market.

Learn More about the Clinical and Commercial Development Activities in the Waldenstrom's Macroglobulinaemia Therapeutics Domain:
https://www.delveinsight.com/report-store/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Waldenstrom's Macroglobulinaemia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Waldenstrom's Macroglobulinaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Request for Sample PDF to Understand More About the Waldenstrom's Macroglobulinaemia Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Waldenstrom's Macroglobulinaemia Therapeutics Analysis
There are approx. 20+ key companies developing the therapies for Waldenstrom's Macroglobulinaemia. Currently, Ascentage Pharma is leading the therapeutics market with its Waldenstrom's Macroglobulinaemia drug candidates in the most advanced stage of clinical development.

Waldenstrom's Macroglobulinaemia Companies in the Therapeutics Market Include:
• Amgen
• Abbvie
• Roche
• Bristol-Myers Squibb
• X4 Pharmaceuticals
• TransThera Sciences
• BeiGene
• Janssen
• Ascentage Pharma
• Gilead Sciences
• ADC Therapeutics
• InnoCare Pharma
• Mustang Bio
And many others

Emerging and Marketed Waldenstrom's Macroglobulinaemia Therapies Covered in the Report Include:
• Lisaftoclax: Ascentage Pharma
• ABT199: Abbvie
• TT-01488: TransThera Biosciences
And Many More

Get an in-depth Assessment of the Emerging Therapies and Waldenstrom's Macroglobulinaemia Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Waldenstrom's Macroglobulinaemia Current Treatment Patterns
4. Waldenstrom's Macroglobulinaemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Waldenstrom's Macroglobulinaemia Late-Stage Products (Phase-III)
7. Waldenstrom's Macroglobulinaemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Waldenstrom's Macroglobulinaemia Discontinued Products
13. Waldenstrom's Macroglobulinaemia Product Profiles
14. Waldenstrom's Macroglobulinaemia Companies
15. Waldenstrom's Macroglobulinaemia Drugs
16. Dormant and Discontinued Products
17. Waldenstrom's Macroglobulinaemia Unmet Needs
18. Waldenstrom's Macroglobulinaemia Future Perspectives
19. Waldenstrom's Macroglobulinaemia Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Messenger RNA (mRNA)-based Vaccines and Therapeutics Market
https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market

Narcolepsy Market
https://www.delveinsight.com/report-store/narcolepsy-market

Osteoporosis Market
https://www.delveinsight.com/report-store/osteoporosis-market

Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market

Migraine Market
https://www.delveinsight.com/report-store/migraine-market

Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market

Substance use disorder Market
https://www.delveinsight.com/report-store/substance-use-disorder-market

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market

Campylobacter Infections Market
https://www.delveinsight.com/report-store/campylobacter-infections-market

mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market

Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market

Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market

Obsessive-Compulsive Disorder Market
https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market

Diabetic Eye Disease Market
https://www.delveinsight.com/report-store/diabetic-eye-disease-market

Seborrhoeic Dermatitis Market
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market

Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Waldenstrom's Macroglobulinaemia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Amgen, Abbvie, Roche, TransThera, BeiGene, Janssen, Ascentage, Gilead, InnoCare Pharma, Mustang Bio here

News-ID: 3134187 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Waldenstrom

Waldenstrom Macroglobulinemia Market Positioned for Accelerated Development Thro …
DelveInsight's "Waldenstrom Macroglobulinemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Waldenstrom Macroglobulinemia, historical and forecasted epidemiology as well as the Waldenstrom Macroglobulinemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Waldenstrom Macroglobulinemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Waldenstrom Macroglobulinemia Market Forecast https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Expected to Re …
DataM Intelligence has released a new research report on the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors
Waldenstrom Macroglobulinemia Market to Reach US$ 229.1 Million by 2033
Market Overview: The waldenstrom macroglobulinemia market reached a value of US$ 146.0 Million in 2022 and expects to reach US$ 229.1 Million by 2033, exhibiting a growth rate (CAGR) of 4.17% during 2023-2033. According to the IMARC Group, the waldenström macroglobulinemia market exhibited a market size of US$ 229.1 Million in the year 2033 and is projected at a CAGR of 4.17% during 2023-2033. This can be attributed to the emerging popularity
Waldenstrom Macroglobulinemia Therapeutics Market Sluggish Growth Rate Foreseen …
The Waldenstrom Macroglobulinemia Therapeutics Market size is expected to grow at an annual average of CAGR 4% during the forecast period (2023-2029). Waldenstrom macroglobulinemia (WM) is a rare blood cell cancer characterized by the production of large amounts of an abnormal protein (called macroglobulin) by cancer cells. WM is a type of non-Hodgkin lymphoma (NHL) and is also known as lymphoplasmacytic lymphoma. WM is a low-grade B cell lymphoproliferative neoplasm
Waldenstrom Macroglobulinemia Treatment Market Business Opportunities Forecast t …
According to Precision Business Insights (PBI), latest report, the waldenstrom macroglobulinemia treatment market size was valued at USD 163.7 million in 2022 and is expected to grow at a CAGR of 6.7% during the forecast period 2023 to 2029. The primary factors that drive the market are the growing prevalence of white blood cell lymphoma among geriatric people, rising in new treatment therapies, and the increasing demand for novel drugs
Waldenstrom Macroglobulinemia Market Report- Statistical Analysis, Business Oppo …
The Waldenstrom Macroglobulinemia Market research report segments the market based on type, applications, end-users, and different geographies. Waldenstrom Macroglobulinemia Market helps new entrants/ stakeholders to understand the market trends and plan robust market strategies. Moreover, Waldenstrom Macroglobulinemia Market report also offers a covid-19 impact on the Waldenstrom Macroglobulinemia Market, enabling businesses to understand market drivers and restraints. Get FREE PDF Sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5154352 Waldenstrom Macroglobulinemia Market provides an overview